PharmaJet®, the maker of innovative, needle-free injection technology, today shared that their latest research results were presented at the World Vaccine Congress on April 16, in Washington DC at the Renaissance Washington DC Downtown Hotel.
| GOLDEN, Colo., May 7, 2019 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection technology, today shared that their latest research results were presented at the World Vaccine Congress on April 16, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, was presented by Dr. Marilyn Dysart, Clinical Affairs Manager at PharmaJet, Inc. The PharmaJet injection technology has been proven safe and effective with commercial vaccines and pharmaceuticals including influenza, MMR, HPV, polio, and others. In addition, an increasing amount of data is showing superior efficacy over other delivery methods with nucleic acid-based platforms for vaccines, passive antibodies, and personalized medicine. The Needle-free devices have gained regulatory clearances both in the US and Europe, and in various other markets, and they are also pre-qualified (PQS) by the World Health Organization. “The PharmaJet devices are now in use with over 50 novel pharmaceuticals, mostly Nucleic acid platforms, in pre-clinical and clinical studies globally, and the data has continued to show robust safety and overwhelmingly positive clinical efficacy,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet, Inc. “Our collaborators are using this technology to enable their transition from animal studies into human trials and potential licensure.” For more information about PharmaJet visit www.pharmajet.com. Refer to Instructions for Use to ensure safe injections and to review risks. 1 Data on file About PharmaJet CONTACT:
SOURCE PharmaJet |
View original content:
